We have observed
5 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Combination treatments involving antibodies to human PCSK9
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
Method for recombinant production of labyrinthopeptins and functional derivatives thereof